An investigational immune-based induction regimen with Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) demonstrated meaningful clinical efficacy in transplant-eligible patients with newly diagnosed multiple myeloma, according to a news release from Johnson & Johnson. Tecvayli and Darzalex Faspro work synergistically to significantly reduce cancer cells — resulting in deep responses with potential for long term benefit." Cytokine release syndrome (CRS) was observed in 65% of patients (32 patients) and all were grade 1 (mild) or 2 (moderate). The trial is sponsored by the German-Speaking Myeloma Multicenter Group and the German Multiple Myeloma Study Group, and it is being conducted in collaboration with Johnson & Johnson. Reference“TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma.” Johnson & Johnson.